Search results for: 'API organic growth'

Healthcare providers typically manage kidney failure, diabetes, and respiratory failure with large, bulky medical equipment in a hospital setting. Conventional interventions typically reduce patient mobility; the treatment burden, mental anxiety, potential for non-compliance, and other drawbacks for specific therapies can result in poor health outc...

The organ donation and transplant community is facing a constant scarcity of adequate donor organs to meet the unceasingly increasing demand. All innovations in the solid organ transplant industry focus on increasing the availability of donor organs and improving post-transplant outcomes post-transplant. Pre- and post-transplant diagnostics are us...

Artificial organs are support devices that are either attached to the human body or implanted in the human body to restore the function of an ailing organ or to completely replace a native organ. Artificial organs can be segmented into 7 main categories, that is, cochlear implants, artificial heart, artificial liver, artificial pancreas, artificial...

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of ...

Healthcare interoperability, the ability of different healthcare systems and applications to seamlessly exchange and use patient health data, is critical to advanced, precise, and personalized healthcare. Data interoperability is crucial to advanced, precise, and personalized healthcare; however, achieving interoperability has been a significant ch...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...